NORWOOD, MA, MARCH 3, 2010 -- Molecular Biometrics®, Inc., a metabolomics company developing novel clinical diagnostic tools for applications in personalized medicine, today announced that ViaMetrics-E™, a rapid, non-invasive procedure designed to enhance in vitro fertilization (IVF) outcomes, is now available commercially in Australia, Japan, the U.K., Ireland and Greece. ViaMetrics-E is designed to aid in the identification of embryos having the greatest reproductive potential, thus improving IVF pregnancy rates, and ultimately reducing the number of embryos transferred during an IVF cycle, along with the complications and healthcare costs that accompany multiple births. The company expects to launch the product in other countries in Europe and Asia in 2010.

“The non-invasive and physiological assessment of an embryo’s reproductive potential is the ‘holy grail’ of infertility treatment. As an adjunct to morphological (i.e., anatomical) evaluation of an embryo, ViaMetrics-E can help clinicians evaluate an embryo’s reproductive potential based on biological evidence rather than just observational evidence. We believe this will be a major advance in the treatment of infertility and will give clinicians and patients alike greater confidence in transferring fewer embryos to achieve pregnancy, thereby reducing the potential for multiple births,” said James T. Posillico, PhD, President and Chief Executive Officer, Molecular Biometrics. “I am very proud and grateful to the Molecular Biometrics team, investors and research partners for their dedication, commitment and expertise in helping to bring ViaMetrics-E to the market. This is a tremendous milestone for our company.”

In 2009, the company successfully completed a 20-week beta testing program at 13 infertility centers in Australia, the U.K., Ireland and Japan. The findings from the beta test contributed to the optimization of the final commercial product. The company now expects ViaMetrics-E to achieve widespread availability in several countries by year end. Molecular Biometrics is also working to complete the necessary regulatory requirements for clearance from the U.S. Food and Drug Administration.

“In the U.K., and worldwide, there is a major effort underway to reduce the number of multiple births following infertility treatment by limiting the number of embryos transferred, or implanted, into the woman’s womb,” said Sue Avery, MD, Director, Assisted Conception Unit, Birmingham Women’s Hospital in the U.K. “The novel technology embodied in ViaMetrics-E is expected to help us achieve that goal, which may, in turn, support single embryo transfer for more patients. This new procedure provides us with another tool to help identify the embryos with the greatest reproductive potential. As a consequence, the IVF community can feel more confident transferring one or two embryo to achieve pregnancy.” Dr. Avery participated in the beta testing program for ViaMetrics-E.

ViaMetrics-E is a rapid, non-invasive procedure for in vitro fertilization (IVF) designed to aid in the assessment of viable embryos with the greatest reproductive potential. As embryos develop they undergo specific metabolic changes and produce biological signals or “biomarkers” that are absorbed into the culture media that nourishes these cells. Using a highly sensitive method of biomarker identification (metabolomics), ViaMetrics-E then measures these signals in the spent culture media, creating a ‘fingerprint’ or biomarker profile to help determine embryo viability. Analysis can be performed in an infertility laboratory in just minutes. ViaMetrics-E provides objective assessment of viability without compromising the embryo, helping guide treatment options for patients undergoing IVF. ViaMetrics-E™ is not currently cleared for use in the U.S. by the Food and Drug Administration.

Molecular Biometrics, Inc. is applying novel metabolomic technologies to develop accurate, non-invasive clinical tools for use in personalized medicine to evaluate normal biologic function in health and in disease, and for drug discovery and development. The company’s proprietary technology is being applied in reproductive health, IVF and neurodegenerative disease (e.g., Parkinson’s disease). Molecular Biometrics is headquartered in Norwood, MA, with research and development facilities in New Haven, CT. For more information, please visit www.molecularbiometrics.com.

Note: This press release contains forward-looking statements about the objectives, plans and future prospects of Molecular Biometrics®, Inc. These statements are based on the company's current expectations and are subject to a number of uncertainties and risks, and actual outcomes and results may differ materially. Accordingly, forward-looking statements should not be regarded as a representation or warranty by Molecular Biometrics or any third party that the company’s objectives and plans will be achieved in any specific time frame, if at all.

CONTACT: Gina Cella
Cella Communications
C: 781-799-3137
O: 781-334-4692
ginacella@comcast.net